Neonates of hepatitis B surface antigen (HBsAg) positive and hepatitis B encoded antigen (HBeAg) positive mothers received 10 micrograms of recombinant hepatitis B vaccine at months 0, 1, 6, or 0, 1, 2, 12, with or without immunoglobulin at birth, and were followed up to the age of 8 years for HBsAg, anti-HBc, and anti-HBs. Some were boosted at month 60. The overall vaccine protection at month ...

background: thalassemia patients are more susceptible to hepatitis than the normal population due to the frequent blood transfusions. objective: to determine the immune response of children with major ß-thalassemia, by measuring anti-hepatitis b surface antibody (anti-hbs ab) following the last hbv vaccine injection. methods: this study was carried out on 215 thalassemic children who received t...

Women (175) who participated in an in vitro fertilization (IVF) programme were possibly exposed to hepatitis B virus. Later it became evident that 79 women had a hepatitis B infection, 49 were exposed but not infected and 47 were not exposed. Hepatitis B immunoglobulin (HBIg) and recombinant hepatitis B vaccine (HBvaxDNA) were offered to all women and partners except for those with established ...

conclusions the study results indicated that the neonatal hbv immunization induced a long-term protection against hbv and was very efficacious in reducing chronic hbv infection rate in vaccinated young adults in iran. results anti-hbs seropositivity rate was detected in 224 of 510 [95% ci: 39-47] young adults. breakthrough infection (positive sera for anti-hbc without chronic infection) was obs...

hepatitis b virus (hbv) infection and its sequelae such as cirrhosis and hepatocellular carcinoma has remained a serious public health problem throughout the world. the who strategy for effective control of hbv infection and its complications is mass vaccination of neonates and children within the framework of expanded programme on immunization (epi). vaccination with hepatitis b surface antige...

Objective: Patients with diabetes mellitus are at increased risk for hepatitis B virus (HBV) infection and its complications. HBV vaccination is recommended for adults with diabetes in the United States and other countries. However, few studies have assessed safety and immunogenicity of hepatitis B vaccine in such patients. We assessed the safety and immunogenicity of recombinant hepatitis B va...

A severe, local, inflammatory, late-phase reaction accompanied by skin necrosis occurred after an infant was given an intramuscular injection of recombinant hepatitis B virus vaccine. The clinical course and appearance of the rash were typical of an Arthus reaction. Although not identical to this case, prior reported cases of complement-mediated reactions occurring after hepatitis B virus infec...

Most hepatitis B (HB) vaccines are based on recombinant major S protein produced and purified from yeast. To decrease the number of vaccinations, several combination vaccines have been developed, and are commonly used for infant [1-3]. These include HB combined with diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP–IPV–HB vaccine); combined hepatitis A and HB va...

1. The response rate to recombinant hepatitis B vaccine was suboptimal (70.1%) in the peritoneal dialysis population. 2. We investigated whether a three-dose regimen of extrahigh dose (80 μg) of Engerix-B would achieve a higher rate of primary seroconversion and more persistent seroprotection in peritoneal dialysis patients, compared with the conventional 40-μg dose. 3. The rates of seroconvers...